Immunomodulating therapy of rheumatoid arthritis by high-dose intravenous immunoglobulin

11 patients with rheumatoid arthritis were treated with intravenous immunoglobulin (IVGG). In 6 patients clinical results were impressive, although lasting responses could be achieved in 3 patients only. This treatment was immunomodulating, since the immunoregulatory T-cell ratio (CD4/CD8) decreased...

Full description

Saved in:
Bibliographic Details
Published inKlinische Wochenschrift Vol. 67; no. 5; p. 286
Main Authors Becker, H, Mitropoulou, G, Helmke, K
Format Journal Article
LanguageEnglish
Published Germany 01.03.1989
Subjects
Adult
Aged
Arthritis, Rheumatoid - immunology
Arthritis, Rheumatoid - therapy
CD4-Positive T-Lymphocytes - immunology
Dose-Response Relationship, Drug
Female
Follow-Up Studies
Humans
Immunoglobulin G - administration & dosage
Immunoglobulin G - analogs & derivatives
Immunoglobulins - analysis
Immunoglobulins, Intravenous
Leukocyte Count
Male
Middle Aged
T-Lymphocytes, Regulatory - immunology
Online AccessGet more information

Cover

More Information
Summary:11 patients with rheumatoid arthritis were treated with intravenous immunoglobulin (IVGG). In 6 patients clinical results were impressive, although lasting responses could be achieved in 3 patients only. This treatment was immunomodulating, since the immunoregulatory T-cell ratio (CD4/CD8) decreased following therapy by reducing CD4-positive cells in-vivo. By use of anti-mu-antibodies as a B-cell specific mitogen, IVGG-treatment was seen to suppress early processes of B cell activation. In parallel to these cellular effects, IVGG led to a reduction in the levels of polyethyleneglycol-precipitated circulating immune complexes as measured by lasernephelometry.
ISSN:0023-2173
DOI:10.1007/BF01892896